SWEET: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy

SWEET is a UK‑wide, multi‑centre randomised clinical trial evaluating an intervention, developed during earlier funded research, to reduce poor adherence to adjuvant endocrine therapy (AET) and improve cancer‑specific health‑related quality of life. In the longer term, the intervention aims to reduce recurrence in women with ER‑positive invasive breast cancer.

A within‑trial economic evaluation is integrated into the study to estimate the cost‑effectiveness of the intervention from the perspective of the UK NHS, patients and society. Long‑term cost‑effectiveness will be modelled, alongside a budget impact assessment.

Funders: NIHR PGfAR